An interventional study of Alendronate, Ibandronate; Risedronate and Teriparatide in Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Khyber Medical University Peshawar. Completed at 1 site in Pakistan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Khyber Medical University Peshawar · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing teriparatide in Osteoporosis, Postmenopausal — 1 open to participants now, 1 under way, none of them phase 3. Teriparatide · Osteoporosis, Postmenopausal.
Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is the only one with no phase, and was the 23rd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 23 studies testing teriparatide in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only · Healthy volunteers
By country, each count listing its studies:
Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 75 across the 22 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 23 have an industry lead sponsor. The 5 most frequent:
Khyber Medical University Peshawar is the lead sponsor of 54 studies on the registry; 11 are open to participants now.
Khyber Medical University Peshawar has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing teriparatide in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06558188Massachusetts General HospitalCombined Anabolic Therapy | 2027-11-02 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 months. In this randomized controlled trial, 40 postmenopausal women with osteoporosis will be assigned to receive either antiresorptive drugs (which slow bone loss) or anabolic drugs (which build new bone), along with calcium and vitamin D. The study will compare how these treatments affect BTMs and BMD over six months to determine if BTMs can serve as an early and reliable indicator of treatment success, which could be particularly useful in regions like Pakistan where access to repeated DEXA scans is limited.
A randomized controlled trial will be conducted to evaluate the association between selective BTM and the efficacy of different drug therapies in primary postmenopausal osteoporotic women. The study is motivated by the high prevalence of osteoporosis in this demographic in Pakistan and the limitations of the current gold standard, BMD measured by DEXA scan, which reflects changes in bone strength at a delayed rate. BTMs, being biochemical indicators of bone formation and resorption, offer a dynamic and rapid assessment of bone metabolic activity, potentially providing an early measure of treatment response within months rather than years. The trial will enroll 40 eligible women over 50, who will be randomly and blindly assigned to one of two treatment groups: one receiving antiresorptive drugs (such as Alendronate) and the other receiving anabolic drugs (Teriparatide), both supplemented with calcium and vitamin D for a six-month period. The primary outcomes include the comparative change in specific BTMs (BsALP, TRACP-5b, and Sclerostin) at three and six months, and the change in BMD at six months. Secondary outcomes will assess the correlation between BTM and BMD changes, as well as fracture incidence and quality of life. By analyzing these parameters, the study aims to generate valuable evidence for the utility of BTMs in guiding and monitoring osteoporosis treatment in a Pakistani clinical setting, potentially leading to more responsive and personalized patient management.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
This study's enrollment of 40 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Browse Osteoporosis, Postmenopausal studies →Khyber Medical University Peshawar is the lead sponsor of 54 studies on the registry; 11 are open to participants now.
Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the anabolic drug Teriparatide 20 mcg, administered as a daily subcutaneous injection, for a duration of 6 months. In addition, all participants in this arm will receive daily Calcium and Vitamin D supplements.
Drug: Teriparatide
Participants will receive one of the following oral antiresorptive drugs for 6 months: Alendronate 70mg weekly, Ibandronate 150mg monthly, or Risedronate 150mg monthly. All participants will also receive Calcium and Vitamin D supplementation.
Drug: Alendronate, Ibandronate; Risedronate
Drug pages: AlendronateStudies of AlendronateAlendronate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Ibandronic AcidStudies of Ibandronic AcidIbandronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Risedronic AcidStudies of Risedronic AcidRisedronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral bisphosphonate tablets. Participants will receive one of the following specific regimens: Alendronate 70mg taken once per week, Ibandronate 150mg taken once per month, or Risedronate 150mg taken once per month. This is combined with daily Calcium and Vitamin D supplementation. The total treatment duration is 6 months.
Also known as: Fosamax; Bonviva; Actonel
A solution for subcutaneous injection. The dosage is 20 micrograms (mcg) injected once daily. This is combined with daily Calcium and Vitamin D supplementation. The total treatment duration is 6 months.
Also known as: Forteo
Change in Bone Turnover Markers (BTMs)
Mean change from baseline in the serum levels of specific bone turnover markers, including the bone formation marker Bone-Specific Alkaline Phosphatase (BsALP) and the bone resorption marker Tartrate-Resistant Acid Phosphatase 5b (TRACP-5b), and the osteocyte marker Sclerostin.
Time frame: Baseline, 3 months, and 6 months.
Change in Bone Mineral Density (BMD)
Mean change from baseline in Bone Mineral Density (BMD) T-score as measured by Dual-Energy X-ray Absorptiometry (DEXA) scans at the hip, spine, and femoral neck.
Time frame: Baseline and 6 months.
Incidence of New Fractures
The number of participants who experience any new fragility fractures during the study period.
Time frame: Through study completion, an average of 6 months.
Plan to share: Yes — A definitive plan for sharing individual participant data has not been established. The data collected, including de-identified individual participant records for primary and secondary outcomes, may be made available upon reasonable request after the primary results are published.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data may become available beginning 6 months after the publication of the primary study findings and will be accessible for a period of 3 years.
Access criteria: Access to IPD will be considered for researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author. Approval will be subject to review by the study's supervisory committee and a signed data sharing agreement.
Ran from Oct 2025 to primary completion in Mar 2026, 5 months.
Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 5 months is below that.
Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teriparatide
Osteoporosis, Postmenopausal →
Khyber Medical University Peshawar